The Effect of Tobacco Control Measures during a Period of Rising Cardiovascular Disease Risk in India: A Mathematical Model of Myocardial Infarction and Stroke

English version České info

Background:
We simulated tobacco control and pharmacological strategies for preventing cardiovascular deaths in India, the country that is expected to experience more cardiovascular deaths than any other over the next decade.

Methods and Findings:
A microsimulation model was developed to quantify the differential effects of various tobacco control measures and pharmacological therapies on myocardial infarction and stroke deaths stratified by age, gender, and urban/rural status for 2013 to 2022. The model incorporated population-representative data from India on multiple risk factors that affect myocardial infarction and stroke mortality, including hypertension, hyperlipidemia, diabetes, coronary heart disease, and cerebrovascular disease. We also included data from India on cigarette smoking, bidi smoking, chewing tobacco, and secondhand smoke. According to the model's results, smoke-free legislation and tobacco taxation would likely be the most effective strategy among a menu of tobacco control strategies (including, as well, brief cessation advice by health care providers, mass media campaigns, and an advertising ban) for reducing myocardial infarction and stroke deaths over the next decade, while cessation advice would be expected to be the least effective strategy at the population level. In combination, these tobacco control interventions could avert 25% of myocardial infarctions and strokes (95% CI: 17%–34%) if the effects of the interventions are additive. These effects are substantially larger than would be achieved through aspirin, antihypertensive, and statin therapy under most scenarios, because of limited treatment access and adherence; nevertheless, the impacts of tobacco control policies and pharmacological interventions appear to be markedly synergistic, averting up to one-third of deaths from myocardial infarction and stroke among 20- to 79-y-olds over the next 10 y. Pharmacological therapies could also be considerably more potent with further health system improvements.

Conclusions:
Smoke-free laws and substantially increased tobacco taxation appear to be markedly potent population measures to avert future cardiovascular deaths in India. Despite the rise in co-morbid cardiovascular disease risk factors like hyperlipidemia and hypertension in low- and middle-income countries, tobacco control is likely to remain a highly effective strategy to reduce cardiovascular deaths.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: The Effect of Tobacco Control Measures during a Period of Rising Cardiovascular Disease Risk in India: A Mathematical Model of Myocardial Infarction and Stroke. PLoS Med 10(7): e32767. doi:10.1371/journal.pmed.1001480
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001480

Souhrn

Zdroje

1. NarayanKM, AliMK, KoplanJP (2010) Global noncommunicable diseases—where worlds meet. N Engl J Med 363: 1196–1198.

2. ReddyKS, YusufS (1998) Emerging epidemic of cardiovascular disease in developing countries. Circulation 97: 596–601.

3. Leeder S, Raymond S, Greenberg H (2004) A race against time: the challenge of cardiovascular disease in developing economies. New York: Columbia University.

4. GlantzS, GonzalezM (2012) Effective tobacco control is key to rapid progress in reduction of non-communicable diseases. Lancet 379: 1269–1271.

5. Shah B, Kumar N, Menon G, Khurana S, Kumar H (2010) Assessment of burden of non-communicable diseases. Delhi: World Health Organization India.

6. JhaP, JacobB, GajalakshmiV, GuptaPC, DhingraN, et al. (2008) A nationally representative case-control study of smoking and death in India. N Engl J Med 358: 1137–1147.

7. World Health Organization (2003) WHO Framework Convention on Tobacco Control. Geneva: World Health Organization.

8. Reddy KS, Gupta PC, editors(2004) Report on tobacco control in India. New Delhi: Government of India Ministry of Health and Family Welfare. Available: http://mohfw.nic.in/WriteReadData/l892s/911379183TobaccocontroinIndia_10Dec04.pdf. Accessed 3 June 2013.

9. LevyDT, MabryPL, GrahamAL, OrleansCT, AbramsDB (2010) Reaching healthy people 2010 by 2013: a SimSmoke simulation. Am J Prev Med 38: S373–S381.

10. LevyDT, NikolayevL, MumfordE (2005) Recent trends in smoking and the role of public policies: results from the SimSmoke tobacco control policy simulation model. Addiction 100: 1526–1536.

11. World Health Organization (2011) Study on global ageing and adult health (SAGE). Geneva: World Health Organization.

12. Tobacco Free Initiative (2011) Global Adult Tobacco Survey (GATS) India report 2009–2010. Geneva: World Health Organization.

13. ThankappanKR, PradeepkumarAS, NichterM (2009) Doctors' behaviour & skills for tobacco cessation in Kerala. Indian J Med Res 129: 249–255.

14. John RM, Rao RK, Rao MG, Moore J, Deshpande RS, et al.. (2010) The economics of tobacco and tobacco taxation in India. Paris: International Union Against Tuberculosis and Lung Disease.

15. AsariaP, ChisholmD, MathersC, EzzatiM, BeagleholeR (2007) Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 370: 2044–2053.

16. LimSS, GazianoTA, GakidouE, ReddyKS, FarzadfarF, et al. (2007) Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 370: 2054–2062.

17. World Health Organization (2012) WHO Global InfoBase [database]. Geneva: World Health Organization.

18. BlecherE (2008) The impact of tobacco advertising bans on consumption in developing countries. J Health Econ 27: 930–942.

19. FichtenbergCM, GlantzSA (2002) Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ 325: 188.

20. KennedyA, SullivanS, HendlinY, BarnesR, GlantzS (2012) Strong tobacco control program requirements and secure funding are not enough: lessons from Florida. Am J Public Health 102: 807–817.

21. KawachiI, ColditzGA, StampferMJ, WillettWC, MansonJE, et al. (1994) Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med 154: 169–175.

22. LightwoodJM, GlantzSA (2009) Declines in acute myocardial infarction after smoke-free laws and individual risk attributable to secondhand smoke. Circulation 120: 1373–1379.

23. Pacific Tobacco Taxation Project, World Health Organization (2012) Higher tobacco taxes save lives! Sydney: Pacific Tobacco Taxation Project.

24. FriedenTR, MostashariF, KerkerBD, MillerN, HajatA, et al. (2005) Adult tobacco use levels after intensive tobacco control measures: New York City, 2002–2003. Am J Public Health 95: 1016–1023.

25. GazianoTA, OpieLH, WeinsteinMC (2006) Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 368: 679–686.

26. TanCE, GlantzS (2012) Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: a meta-analysis. Circulation 126: 2177–2183.

27. GrassiMC, EneaD, FerketichAK, LuB, NenciniP (2009) A smoking ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year. Nicotine Tob Res 11: 1114–1121.

28. JhaP, ChaloupkaFJ (2000) The economics of global tobacco control. BMJ 321: 358.

29. ChisholmD, DoranC, ShibuyaK, RehmJ (2006) Comparative cost-effectiveness of policy instruments for reducing the global burden of alcohol, tobacco and illicit drug use. Drug Alcohol Rev 25: 553–565.

30. GazianoTA, GaleaG, ReddyKS (2007) Scaling up interventions for chronic disease prevention: the evidence. Lancet 370: 1939–1946.

31. KenfieldSA, StampferMJ, RosnerBA, ColditzGA (2008) Smoking and smoking cessation in relation to mortality in women. JAMA 299: 2037–2047.

32. Registrar General & Census Commissioner (2011) Census of India. Delhi: Ministry of Home Affairs.

33. World Health Organization (2008) Disease and injury country estimates. Geneva: World Health Organization.

34. SadikotSM, NigamA, DasS, BajajS, ZargarAH, et al. (2004) The burden of diabetes and impaired glucose tolerance in India using the WHO 1999 criteria: prevalence of diabetes in India study (PODIS). Diabetes Res Clin Pract 66: 301–307.

35. DanaeiG, FinucaneMM, LuY, SinghGM, CowanMJ, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31–40.

36. TeoKK, OunpuuS, HawkenS, PandeyMR, ValentinV, et al. (2006) Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368: 647–658.

37. BarnoyaJ, GlantzSA (2005) Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 111: 2684–2698.

38. CallinanJE, ClarkeA, DohertyK, KelleherC (2010) Legislative smoking bans for reducing secondhand smoke exposure, smoking prevalence and tobacco consumption. Cochrane Database Syst Rev 2010: CD005992.

39. SteadLF, BergsonG, LancasterT (2008) Physician advice for smoking cessation. Cochrane Database Syst Rev 2008: CD000165.

40. BalaM, StrzeszynskiL, CahillK (2008) Mass media interventions for smoking cessation in adults. Cochrane Database Syst Rev 2008: CD004704.

41. Saffer H, Chaloupka F (1999) Tobacco advertising: economic theory and international evidence. Cambridge: National Bureau of Economic Research.